ATE308522T1 - Opioidrezeptorantagonisten - Google Patents

Opioidrezeptorantagonisten

Info

Publication number
ATE308522T1
ATE308522T1 AT03733973T AT03733973T ATE308522T1 AT E308522 T1 ATE308522 T1 AT E308522T1 AT 03733973 T AT03733973 T AT 03733973T AT 03733973 T AT03733973 T AT 03733973T AT E308522 T1 ATE308522 T1 AT E308522T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
opioid receptor
racemate
diastereomers
enantiomer
Prior art date
Application number
AT03733973T
Other languages
English (en)
Inventor
Charles Howard Mitch
Steven James Quimby
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE308522T1 publication Critical patent/ATE308522T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03733973T 2002-05-30 2003-05-22 Opioidrezeptorantagonisten ATE308522T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38460302P 2002-05-30 2002-05-30
PCT/US2003/014540 WO2003101963A1 (en) 2002-05-30 2003-05-22 Opioid receptor antagonists

Publications (1)

Publication Number Publication Date
ATE308522T1 true ATE308522T1 (de) 2005-11-15

Family

ID=29712067

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03733973T ATE308522T1 (de) 2002-05-30 2003-05-22 Opioidrezeptorantagonisten

Country Status (7)

Country Link
US (1) US20050222204A1 (de)
EP (1) EP1513813B1 (de)
AT (1) ATE308522T1 (de)
AU (1) AU2003239389A1 (de)
DE (1) DE60302157T2 (de)
ES (1) ES2249722T3 (de)
WO (1) WO2003101963A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572332T3 (es) 2000-10-31 2016-05-31 Rensselaer Polytech Inst 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides
IL161157A0 (en) 2001-10-22 2004-08-31 Pfizer Prod Inc 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
US20040204453A1 (en) * 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
CA2558030A1 (en) 2004-03-15 2005-09-29 Eli Lilly And Company 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
AU2012200919B2 (en) * 2005-10-27 2015-05-28 Merck Sharp & Dohme Llc Novel opioid antagonists
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
CN101426481B (zh) 2006-04-21 2012-12-05 帝斯曼知识产权资产管理有限公司 阿片受体拮抗剂的用途
EP2064199A1 (de) 2006-09-08 2009-06-03 Pfizer Products Inc. Diaryletherderivate und anwendungen davon
EP2152671A1 (de) 2007-05-22 2010-02-17 Prosidion Limited Bicyclische aryl- und heteroarylverbindungen zur behandlung von stoffwechselerkrankungen
EP2197835A1 (de) 2007-09-07 2010-06-23 Prosidion Limited Bicyclische aryl- und heteroarylverbindungen als rezeptormodulatoren
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
US20100311782A1 (en) * 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
ES2729679T3 (es) 2009-12-04 2019-11-05 Alkermes Pharma Ireland Ltd Derivados de morfinano para el tratamiento de la sobredosis de fármacos
WO2011119605A2 (en) 2010-03-22 2011-09-29 Rensselaer Polytechnic Institute Carboxamide biosiosteres of opiates
ES2705726T3 (es) 2010-08-23 2019-03-26 Alkermes Pharma Ireland Ltd Métodos para tratar el aumento de peso inducido por antipsicóticos
WO2012138888A1 (en) 2011-04-05 2012-10-11 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
EP2725908B1 (de) 2011-06-29 2017-05-31 Alkermes, Inc. Peripher wirkende opioidverbindungen
ES2692771T3 (es) 2011-12-15 2018-12-05 Alkermes Pharma Ireland Limited Samidorfano (ALKS 33) en combinación con buprenorfina para el tratamiento de trastornos depresivos
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP3003311A2 (de) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Verfahren zur behandlung von symptomen für depression
JP2016519161A (ja) 2013-05-24 2016-06-30 アルカームス ファーマ アイルランド リミテッド モルファン及びモルフィナン類似物及び使用の方法
EP4243768A1 (de) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Mehrschichttablette mit sofortiger freisetzung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
AU2003239389A1 (en) 2003-12-19
DE60302157T2 (de) 2006-07-27
WO2003101963A1 (en) 2003-12-11
EP1513813A1 (de) 2005-03-16
US20050222204A1 (en) 2005-10-06
ES2249722T3 (es) 2006-04-01
DE60302157D1 (de) 2005-12-08
EP1513813B1 (de) 2005-11-02

Similar Documents

Publication Publication Date Title
ATE406360T1 (de) Antagonisten der opioidrezeptoren
DE60302157D1 (de) Opioidrezeptorantagonisten
ATE377589T1 (de) 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
ATE324371T1 (de) N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten
MY130803A (en) New quinuclidine amide derivatives
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
DE602004024375D1 (de) Carboxamidderivate
TW200505902A (en) Cannabinoid receptor ligands
ATE399770T1 (de) Tachykininrezeptorantagonisten
WO2004000808A3 (en) N-substituted piperidine derivatives as serotonin receptor agents
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
WO2004082623A3 (en) Substituted piperidine compounds
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
DK1440059T3 (da) 3-azabicyclo(3.1.0)hexanderivater som opioidreceptorantagonister
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
IL172542A0 (en) 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
DK1814848T3 (da) 2,3,4-substitueret-cyclopentanoner som terapeutiske midler
ATE389405T1 (de) Fexofenadine hydrochlorid polymorph
MXPA05011476A (es) Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2.
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
WO2004103305A3 (en) Spiropyrazole compound
ITVR20020030A0 (it) Miscela per polvere di saldatura, nonche procedimento per l'impiego di detta miscela.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties